This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
Featured Open Lecture: January-February 2020
Share |

Introducing Featured Open Lectures

This is a new initiative from the Society to highlight our online educational platform EAS ACADEMY. Every other month we select one interesting lecture from a recent course or congress and make it available for free, to members and non-members.

Open Lecture January/February 2020

Inflammation, Inhibition and Atherothrombosis, EAS Academy,Professor Paul Ridker, Havard Medical School, Boston, USA.

This is a keynote lecture given by Professor Paul Ridker at the 87th EAS Congress in Maastricht, May 26-29, 2019. Professor Ridker is the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention, at the Brigham and Women’s Hospital in Boston.
In his excellent and up-to-date overview, Professor Ridker discussed the potential to use anticytokine agents targeting specific interleukin signaling pathways for the treatment of atherothrombosis. He presented new data form the CANTOS trial according to which the reduction of MACEs by canakinumab is consistent across several patient subgroups participated in the trial, such as men/women, diabetics/non-diabetics, smokers/non-smokers, obese/non-obese, etc. He emphasized that the CANTOS trial provides proof-of-principle that inflammation inhibition, in the absence of lipid lowering, can improve atherothrombotic outcomes. In addition he showed that canakinumab reduces cardiovasular and all-cause mortality as well as hospitalization for heart failure or heart failure-related mortality. He also discussed the role of inflammation in tumour progression and presented data from the CANTOS trial according to which canakinumab reduces the incidence of lung cancer as well as the fatal lung cancer.
Furthermore, he presented data related to non-pharmacologic approaches to inhibit inflammation, focused on the anit-inflammatory effects of dietary interventions. He concluded that quality cardiovascular care requires to recognize the distinction between residual cholesterol risk and residual inflammatory risk, as these patient groups have different reasons for recurrent events. It is a very important and comprehensive lecture you should not miss.

To the Featured Open Lecture on EAS ACADEMY >>

 

 

Membership Software Powered by YourMembership  ::  Legal